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Abstract
Polymicrobial sepsis is characterized by an early, hyperdynamic phase followed by a late, hypodynamic phase. Although
studies have suggested that endothelins (ETs) contribute to the development of shock after a bolus injection of endotoxin,
little is known about the role of ETs in the transition from the hyperdynamic phase to the hypodynamic phase of sepsis. To
study this, male adult rats were subjected to sepsis by cecal ligation and puncture (CLP) followed by fluid resuscitation.
Plasma levels of ET-1 and ET-2 were measured by radioimmunoassay at 2, 5, 10 h (i.e. the early stage of sepsis), and 20 h
(late stage) following CLP or sham operation. Tissue levels of ET-1 and ET-2 were determined in the heart, lungs, small
intestine, and spleen at 5 h after CLP or sham operation. In addition, preproendothelin-1 (precursor of ET-1) gene expression
was analyzed by reverse transcription-polymerase chain reaction (RT-PCR) at 5 h in the heart, lungs, small intestine, spleen,
and liver. The results indicate that plasma levels of ET-1 and ET-2 were not different from values of sham groups at 2 and 20
h, but were significantly higher than the sham values at 5 and 10 h after CLP. While there were no significant increases in
tissue levels of ET-1 and ET-2 at 5 h post-CLP, RT-PCR analysis indicates a significant upregulation of preproendothelin-1
gene expression in the heart, spleen, and liver (but not in the lungs or small intestine) at 5 h after the onset of sepsis. These
results indicate that the heart, spleen, and liver appear to be important ET-producing organs during the early stage of sepsis.
The lack of significant increases in tissue ET levels could be due to the possibility that the newly converted peptide is quickly
transferred to the bloodstream. Since the hyperdynamic phase of sepsis occurs at 2^10 h and the hypodynamic phase occurs
at 20 h after CLP, the increased plasma levels of ET at 5 and 10 h suggest that mediators other than ETs (such as
adrenomedullin) are responsible for producing the biphasic hemodynamic responses during the progression of polymicrobial
sepsis. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
While therapeutic approaches for the management
of sepsis have advanced in recent years, the incidence
of septic shock has increased signi¢cantly over the
past 20 years, and it remains the leading cause of
death among surgical intensive care patients [1,2].
There are two distinct phases associated with poly-
microbial sepsis. The early, hyperdynamic phase is
characterized by increased cardiac output and tissue
perfusion and decreased vascular resistance, and the
later, hypodynamic phase is characterized by reduced
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cardiac output and tissue perfusion [2,3]. A recent
study by Szalay et al. has indicated that endothelins
play a role in producing the hypodynamic response
during sepsis by showing that blockade of
endothelinA (ETA) receptors attenuates the increased
total peripheral resistance and decreased cardiac out-
put observed during hypodynamic sepsis [4]. If ETA
receptor binding does in fact contribute to the hemo-
dynamic response seen during hypodynamic sepsis,
one would expect an increase in circulating levels
of the ligand (i.e. ET-1 and ET-2, potent vasocon-
strictors) under such conditions. We tested the hy-
pothesis that upregulation of ETs closely coincides
with the initiation of the hypodynamic phase of sep-
sis by determining at what time points circulating
levels of ETs are increased. In addition, recent stud-
ies have shed light on the relationship between ETs
and other known mediators of sepsis, including
TNF-K and IL-1L [5^8]. These cytokines have been
shown to upregulate ET-1 gene expression in various
cell populations [6,7].
Endothelins belong to a family of bicyclic 21-ami-
no acid residue peptides, which also includes sarafo-
toxins, mouse vasoactive intestinal contractor, and
bibrotoxin. Three ET isopeptides (ET-1, ET-2, and
ET-3) are the most potent known vasoconstrictors of
vascular smooth muscle, and their pharmacological
roles in various tissue beds are well documented [9^
12]. The strong vasoactive properties of ETs have led
to speculation that they might play an integral role in
the hemodynamic changes associated with sepsis syn-
drome. ET-1 was ¢rst isolated from porcine aorta
endothelial cells in 1988 by Yanagisawa et al. [9].
Shortly after, ET-2 and ET-3 were sequenced [13].
Although ET isopeptides possess a highly conserved
primary structure, they di¡er in their receptor selec-
tivity and biological activities [14^16]. In this regard,
ET-1’s a⁄nity for ETA receptors is 8 times as strong
as ET-2’s, and 1000 times as strong as ET-3’s. Since
ETA receptors primarily mediate vasoconstriction,
ET-1 is therefore considered the predominant vaso-
constrictive isopeptide. The three isopeptides show
similar potency for ETB receptors, which elicit both
vasoconstriction and vasodilation, depending on
their localization. Karne et al. have cloned an ET-
3-selective receptor, termed ETC, from Xenopus lae-
vis, though a mammalian source has yet to be found
[17]. Since ET-1’s potency is similar to or greater
than the others, it appears that ET-1 is the predom-
inant isopeptide during sepsis. Endothelins are pro-
duced by a three-stage synthetic pathway. Transcrip-
tion of the ET genes yields 203^212-amino acid
residue proteins called preproendothelins, which are
cleaved by speci¢c endopeptidases to form big ETs.
Final conversion of these precursors into mature ETs
is accomplished by proteases known as ET convert-
ing enzymes.
Circulating levels of ETs have been shown to in-
crease in various cardiovascular, renal, and respira-
tory disorders, all of which are associated with dam-
age to the vascular endothelium [18]. Plasma levels of
ET-1 and ET-3 are elevated in septic patients [19^24],
and the levels of ETs are positively correlated with
the severity of the illness [24]. It has been suggested
that the release of ETs during sepsis has both bene-
¢cial and detrimental e¡ects. While their vasocon-
stricting e¡ects may counteract the general hypoten-
sion and decreased cardiac output associated with
septic shock, ETs also contribute to the increased
vascular resistance that can eventually lead to multi-
ple organ failure. Alterations in plasma and tissue
concentrations of ETs have been well documented
during various endotoxemia models [25^27]. Few
studies, however, have employed the cecal ligation
and puncture (CLP) model of sepsis, with its clearly
de¢ned hyperdynamic and hypodynamic phases, to
examine the role ETs during polymicrobial sepsis.
The aim of this study, therefore, was to determine
at which time point plasma endothelin concentra-
tions are increased and which organs contribute to
increased endothelin levels during polymicrobial sep-
sis.
2. Materials and methods
2.1. Animal model of polymicrobial sepsis
Male Sprague^Dawley rats (275^325 g) were sub-
jected to polymicrobial sepsis by CLP [28]. Brie£y,
rats were fasted overnight, but allowed water ad li-
bitum. After anesthetization with methoxy£urane in-
halation, a 2-cm ventral midline incision was made,
and the cecum was exposed and ligated just distally
to the ileocecal valve. The cecum was then punctured
twice with an 18-gauge needle, squeezed slightly to
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allow a small amount of fecal matter to £ow from
the holes, and then returned to the abdominal cavity.
The incision was closed in layers and the wound was
bathed in 1% lidocaine solution to provide analgesia.
The animal received a subcutaneous injection of nor-
mal saline (3 ml/100 g body weight) immediately
after CLP (i.e. £uid resuscitation). Sham-operated
animals were subjected to the same procedure though
the cecum was neither ligated nor punctured. The
experiments described herein were performed in ad-
herence to the National Institutes of Health guide-
lines for the use of experimental animals. This proj-
ect was approved by the Institutional Animal Care
and Use Committee of Rhode Island Hospital (Prov-
idence, RI).
2.2. Determination of plasma and tissue levels of ETs
Blood samples were drawn at 2, 5, 10, and 20 h
following CLP or sham-operation by cardiac punc-
ture under methoxy£urane anesthesia (n = 8^10 rats
at each time point). Samples were also collected from
a normal control group which underwent no opera-
tion. Because multiple sampling may signi¢cantly af-
fect blood pressure and cardiac output, repeated
blood samples were not taken from the same animal
at di¡erent time points. Blood was drawn into a
heparinized syringe, immediately placed on ice, and
then centrifuged at 3000 rpm at 4‡C for 10 min using
a Sorvall RT6000D centrifuge (DuPont, Ho¡man
Estates, IL). Plasma was frozen in 1.5-ml aliquots
and stored at 380‡C until assay. Plasma levels of
ET-1, ET-2, and big ET-1 were measured using a
speci¢c radioimmunoassay kit (Endothelin-1,2 (high
sensitivity) (125I) assay system, Amersham, Arlington
Heights, IL). Brie£y, ETs were extracted from acidi-
¢ed plasma samples using Amprep 500 mg C2 col-
umns (Amersham, Arlington Heights, IL) and eluted
with 80% acetonitrile and 0.1% tri£uoroacetic acid.
The eluant was then evaporated overnight in a cen-
trifugal concentrator (Savant Speed Vac Plus
SC110A, Savant Instruments, Farmingdale, NY), re-
constituted in assay bu¡er, and analyzed according
to the manufacturer’s protocol. In additional groups
of animals, the heart, lungs, small intestine, and
spleen were harvested at 5 h after CLP or sham-op-
eration and snap frozen in liquid nitrogen. The tissue
samples were then homogenized in 25% 2 M HCl,
centrifuged at 3000 rpm for 30 min, and the super-
natant was frozen at 380‡C. ETs were extracted and
assayed as described above.
2.3. Reverse-transcription polymerase chain reaction
(RT-PCR)
Heart, liver, spleen, lung, and small intestine sam-
ples were harvested at 5 h after CLP or sham-oper-
ation. Total RNA was extracted using Tri-reagent
(Molecular Research Center, Cincinnati, OH) and
4 Wg of RNA was reverse transcribed as previously
described by us [29]. The resulting cDNAs were am-
pli¢ed by polymerase chain reaction (PCR) using
speci¢c primer for rat preproendothelin-1 (pre-
proET-1, sense, 5P-GCTCCAGAAACAGCTGTCT-
TGGGA-3P ; antisense, 5P-GGAGGTCTTGATGC-
TGTTGCTGA-3P) [30]. Rat glyceraldehyde 3-
phosphate dehydrogenase (G3PDH) served as a
housekeeping gene (Clontech, Palo Alto, CA). PCR
cycling proceeded as follows: 94‡C for 1 min, 58‡C
for 2 min, and 72‡C for 3 min. Heart, small intestine,
and liver samples were ampli¢ed with 35 cycles, lung
and spleen samples with 30 cycles, and G3PDH sam-
ples with 25 cycles. Following the RT-PCR proce-
dure, the PCR ampli¢cation products were electro-
phoresed using a 1.6% agarose gel containing 0.22
Wg/ml ethidium bromide. The gel was then photo-
graphed using Polaroid ¢lm.
2.4. Statistical analysis
Results are presented as means þ S.E.M. One-way
analysis of variance and Tukey’s test or unpaired
Student’s t-test was used and the di¡erences were
considered signi¢cant at P9 0.05.
3. Results
3.1. Alterations in plasma ET levels
Alterations in plasma levels of ETs (the sum of
ET-1, ET-2, and big ET-1, which cannot be sepa-
rately measured by the current RIA) are summarized
in Fig. 1. At 2 h after CLP, there were no signi¢cant
increases in plasma ETs. At 5 and 10 h after CLP,
however, septic animals showed approximately a
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two-fold increase as compared to sham-operated and
normal rats (P6 0.05, 16.4 þ 1.74 versus 7.7 þ 0.5 pg/
ml at 5 h, and 19.7 þ 1.7 versus 11.56 þ 1.0 pg/ml at
10 h; plasma levels in normal rats were 11.7 þ 1.2 pg/
ml). At 20 h after CLP, concentrations of plasma
ETs returned to sham levels (Fig. 1).
3.2. Alterations in tissue ET levels
As indicated in Fig. 2, cardiac ET levels in septic
animals were not signi¢cantly di¡erent from sham-
operated animals. Similarly, there were no signi¢cant
alterations in ET levels in the lungs, small intestine,
or spleen at 5 h after the onset of sepsis.
3.3. Alterations in preproET-1 gene expression
The RT-PCR results in Fig. 3C indicate that pre-
proET-1 gene expression increased in the heart (lane
3, 488 bp) and liver (lane 7) at 5 h after the onset of
Fig. 1. Plasma levels of endothelins at various time-points after
cecal ligation and puncture (CLP) or sham operation (Sham).
The data are presented as means þ S.E.M.(n = 7^10/group) and
compared by one-way analysis of variance and Tukey’s test.
*P6 0.05 versus the respective sham-operated animals.
Fig. 2. Tissue levels of endothelins at 5 h after cecal ligation
and puncture (CLP) or sham operation (Sham). The data are
presented as means þ S.E.M. (n = 5^7/group) and compared by
unpaired Student’s t-test. *P6 0.05 versus the respective sham-
operated animals.
Fig. 3. Gene expression of preproendothelin-1 (488 bp) (A,C)
as well as the housekeeping gene G3PDH (983 bp) (B,D) in the
lungs, spleen, heart, small intestine, and liver at 5 h after cecal
ligation and puncture or sham operation. (A) Lane 1, X174/
HaeIII size markers; lane 2, lung preproET-1 in sham animals;
lane 3, lung preproET-1 in CLP animals; lane 4, splenic pre-
proET-1 in sham animals; lane 5, splenic preproET-1 in CLP
animals. (B) Lane 1, X174/HaeIII size markers; lane 2, lung
G3PDH in shams; lane 3, lung G3PDH in CLPs; lane 4,
splenic G3PDH in shams; lane 5, splenic G3PDH in CLPs. (C)
Lane 1, X174/HaeIII size markers; lane 2, cardiac preproET-1
in shams; lane 3, cardiac preproET-1 in CLPs; lane 4, intesti-
nal preproET-1 in shams; lane 5, intestinal preproET-1 in
CLPs; lane 6, hepatic preproET-1 in shams; lane 7, hepatic
preproET-1 in CLPs. (D) The order of each lane is identical to
that in C, with the exception that lane 2 here is a G3PDH posi-
tive control.
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sepsis as compared to sham-operated animals (lanes
2 and 6, respectively). Similarly, preproET-1 mRNA
levels increased signi¢cantly in the spleen (lane 5,
Fig. 3A) at 5 h as compared to shams (lane 4, Fig.
3A). Fig. 3B and D indicate that expression of the
housekeeping gene G3PDH (983 bp) was similar in
both sham and CLP groups in all of the tissues
tested, indicating that similar levels of reverse tran-
scription were achieved. Optical density of target and
housekeeping gene bands were determined by Mocha
Image Analysis and Sigma Gel software. PreproET-
1/G3PDH band density ratios were calculated. The
results indicate that the preproET-1/G3PDH ratio
increased signi¢cantly in the heart, liver, and spleen,
but not in the lungs and small intestine at 5 h after
the onset of sepsis (Fig. 4).
4. Discussion
Endothelin-1 is the most potent known vasocon-
strictor released by vascular endothelial cells [9^11].
As such, members of the ET family of isopeptides, in
conjunction with eicosanoids and other vasoactive
substances such as nitric oxide (NO), are thought
to play a key role in regulating hemodynamic re-
sponses that take place during various disease states,
including sepsis [24,31^34]. There is some controv-
ersy, however, as to whether the role ETs is bene¢cial
or detrimental. Wanecek et al. reported that ad-
ministration of the mixed non-peptide ET receptor
antagonist bosentan counteracted the cardiac dys-
function seen during endotoxemia by reducing sys-
temic vascular resistance and improving stroke vol-
ume index and systemic oxygen delivery [35].
Conversely, Ruetten et al. administered the non-se-
lective ET receptor antagonist SB 209670 after endo-
toxin infusion and reported an exacerbation of hypo-
tension, vascular hyporeactivity to norepinephrine,
renal dysfunction, and hepatocellular injury as com-
pared to rats receiving endotoxin alone [36]. In con-
trast to endotoxin, the role of ETs in the progression
of polymicrobial sepsis remains unclear.
Although studies have documented deviations in
plasma and tissue concentrations of ETs following
endotoxin injection or in a cecal-slurry model of sep-
sis [25^27], little research has been conducted on this
subject using the CLP model of polymicrobial sepsis.
This model of sepsis closely mimics the hemodynam-
ic changes that occur in the usual clinical arena,
where an early, hyperdynamic phase (characterized
by increased tissue perfusion and cardiac output,
and decreased total peripheral resistance) is followed
by a late, hypodynamic phase (characterized by re-
duced cardiac output and tissue perfusion) [3]. The
studies of Szalay et al. suggest that ET-1 might play
a role in producing the hypodynamic phase by show-
ing that ET-A receptor blockade attenuates the in-
creased total peripheral resistance and decreased car-
diac output seen during hypodynamic sepsis [4].
Little is known, however, about what role, if any,
ETs play in producing the hypodynamic phase of
polymicrobial sepsis, or the transition from the hy-
perdynamic response to the hypodynamic response
of sepsis. The purpose of the present study, therefore,
was to determine at which time point plasma ET
concentrations are increased and which organs con-
tribute to increased ET levels during polymicrobial
sepsis.
Our results indicate that plasma levels of ETs (ET-
1, ET-2, and big ET-1) were signi¢cantly increased at
5 and 10 h after CLP, but remained close to sham
levels at 2 and 20 h after CLP. The lack of the in-
crease in plasma concentrations of ETs during the
late stage of sepsis is consistent with the ¢ndings of
other investigators using cecal slurry and LPS infu-
sion models in rats and sheep [26,27]. In contrast, the
increased ET levels appear to occur much earlier
Fig. 4. The intensity ratio of preproendothelin-1 gene versus
housekeeping gene G3PDH in various organs at 5 h after cecal
ligation and puncture (CLP) or sham operation (Sham). The
data are presented as means þ S.E.M. (n = 3^5/group) and com-
pared by unpaired Student’s t-test. *P6 0.05 versus the respec-
tive sham-operated animal.
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following endotoxemia [37]. Since LPS infusion has
been shown to induce pulmonary hypertension and
increased vascular resistance in anesthetized animals
[38], direct administration of endotoxin may produce
a much earlier upregulation of ETs, which appears to
be responsible for intense vasoconstriction. This dis-
crepancy between the models is most likely due to
the accelerated nature of the endotoxin model, which
lacks the distinct phases seen in the CLP model of
sepsis. As a result, direct administration of endotoxin
may produce a much earlier upregulation of ETs.
To determine the source of the upregulated ETs,
tissue levels of ETs were determined in the heart,
lung, small intestine, and spleen at 5 h after CLP.
Though there was a 33% increase in cardiac levels of
ETs, there were no signi¢cant changes in any of the
tissues tested. A few studies have been conducted to
measure tissue levels of ETs during sepsis. Sharma et
al. reported that ET levels in the left ventricle of
septic rats were signi¢cantly increased only at 12 h
following the induction of sepsis by cecal slurry, as
compared to non-septic rats [26]. We propose two
explanations for the lack of signi¢cant increases in
tissue levels of ETs at 5 h after the onset of sepsis.
First, as reported by Lundberg et al., although ETs
appear to be metabolically stable in plasma (with a
half-life of 1^2 min), major local tissue degradation
(ranging from 50^90%) represents a problem when
attempting to measure tissue ET levels [39]. Sec-
ondly, it is possible that the newly synthesized ETs
are quickly released into the bloodstream after con-
version into active peptides, making it di⁄cult to
detect the true increase in tissue levels of ETs during
the course of sepsis. To further investigate the sour-
ces of the upregulated ETs detected in plasma, RT-
PCR was performed to detect preproET-1 gene ex-
pression changes at 5 h after CLP in the heart, lung,
spleen, small intestine, and liver. The signi¢cant up-
regulation observed in the heart, liver, and spleen,
which is consistent with earlier studies [25,40^42],
suggests that these organs are important sources of
the upregulated ETs seen during the early phase of
sepsis. It should be pointed out that only preproET-1
mRNA was assessed in the present study. This was
done since ET-1 appears to be the predominant iso-
peptide in producing vasoconstriction under various
adverse circulatory conditions.
Polymicrobial sepsis is characterized by an early,
hyperdynamic phase followed by a late, hypodynam-
ic phase. We have previously demonstrated that the
hyperdynamic response occurs as early as 2 h after
CLP [3,43]. Since ET production is not upregulated
earlier than 5 h after the onset of sepsis, it does not
appear that ETs play a major role in producing the
hyperdynamic response in early sepsis. It could be
argued that preproET-1 gene upregulation begins
earlier than 5 h after CLP, leading to the production
of mature ET-1 that can act in a paracrine fashion
before it can be detected in the bloodstream. This
possibility is unlikely since locally increased ET levels
should be detected in tissue measurements, but such
increases were absent, even at 5 h post-CLP. Our
recent studies suggest that upregulation of the potent
vasodilatory peptide adrenomedullin (ADM), rather
than ETs, might play an integral role in producing
the hyperdynamic phase associated with early poly-
microbial sepsis [29]. When normal rats were infused
with synthetic rat ADM at a dose which does not
signi¢cantly a¡ect blood pressure, they displayed in-
creased cardiac output, stroke volume, and microvas-
cular blood £ow in various organs and decreased
peripheral resistance [44]. In addition, the hyperdy-
namic and hypercardiovascular responses normally
observed during early sepsis were prevented with ad-
ministration of anti-ADM antibodies [44].
Cytokines such as TNF-K and IL-1L have been
shown to upregulate preproET-1 expression in vari-
ous types of isolated cells [5^8]. Conversely, NO,
whose production during late sepsis is augmented
due to iNOS upregulation [45], downregulates ET-1
production [46]. This late increase in plasma NO
provides one explanation for the return of plasma
ET levels to sham levels during the later stages of
sepsis. It is possible that a delicate balance between
these vasoregulators is disrupted during sepsis, lead-
ing to the diminished vascular tone, peripheral hypo-
perfusion, and multiple organ failure associated with
septic shock.
In summary, our results demonstrate that circulat-
ing levels of ETs were not elevated at 2 or 20 h, but
were signi¢cantly increased at 5 and 10 h after CLP.
While no signi¢cant increases in tissue levels were
detected at 5 h, preproET-1 gene expression was up-
regulated in heart, spleen, and liver at 5 h after CLP.
Since our previous studies have shown that the hy-
perdynamic phase of sepsis begins as early as 2 h
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after CLP, and since ET production is not upregu-
lated earlier than 5 h, we propose that factors other
than ETs are responsible for producing the transition
from the hyperdynamic to the hypodynamic response
during the progression of polymicrobial sepsis.
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